New Tools for the Diagnosis, Prognosis and Treatment Follow-up in Chagas Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

63 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-12-31

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chagas disease is endemic to Latin America, and is of emerging importance in non-endemic countries because migration of people infected with T. cruzi. Current methods for diagnosis of T. cruzi infection are not ideal. Existing drugs for treatment are very limited, produce severe side-effects, and their effectiveness cannot be properly evaluated. Reliable biomarkers for prognosis, early diagnosis and effectiveness of treatment will be investigated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

New Therapies and Biomarkers for Chagas Infection

NCT03981523

Trypanosoma Cruzi Infection Chagas Disease

COMPLETED PHASE2

Chagas Disease Diagnostic - Inconclusive Serology

NCT00511589

Parasitemia Protozoan Infections

COMPLETED NA

Congenital Chagas Disease: Long Term Follow up of Treated Children. Preliminary Report or Cardiological Evaluation in Chagas Disease Treated Children

NCT04090489

Chagas Disease Chagas Cardiomyopathy

COMPLETED

Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram

NCT00453700

Chagas Disease

COMPLETED

Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina

NCT03784391

Chagas' Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chagas Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

No Chagas Disease

Participants with no Chagas Disease will be evaluated as a Control Group

No interventions assigned to this group

Chagas Disease

Participants diagnosed with Chagas Disease will be followed-up as a Case Group

Benznidazole

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Benznidazole

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients from endemic areas (Latin America)
* Older than 18 years old and younger than 50
* With serological confirmation of Chagas Disease infection with two different techniques
* Indeterminate or initial cardiac form
* No previously treated for Chagas Disease

Exclusion Criteria

* Co-morbidity: previous cardiac disease from other aetiology (ischemic, alcoholic or hypertensive), active inflammatory or immunology diseases for another agent. Hepatic disfunction
* Pregnancy or lactation

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes